



Press Release

ABIONYX Pharma announces its financial agenda for the year 2023

Toulouse, FRANCE, Lakeland, UNITED-STATES, January 13, 2023, 7:30 am CET – ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies for patients, today announces its financial agenda for 2023.

Events	Date*
Cash position and activity update for Q4 2022	Tuesday, February 28, 2023
2022 Full-Year Results	Thursday, April 27, 2023
Cash position and activity update for Q1 2023	Wednesday, May 17, 2023
Cash position and activity update for Q2 2023	Thursday, August 17, 2023
2023 Half-Year Results	Thursday, September 28, 2023
Cash position and activity update for Q3 2023	Thursday, November 16, 2023

* indicative dates subject to change

About ABIONYX Pharma

ABIONYX Pharma is a new generation biotech company that aims to contribute to health through innovative therapies in indications where there is no effective or existing treatment, even the rarest ones. Thanks to its partners in research, medicine, biopharmaceuticals and shareholding, the company innovates on a daily basis to propose drugs for the treatment of renal and ophthalmological diseases, or new HDL vectors used for targeted drug delivery.

Contacts:

NewCap

Investor relations
Louis-Victor Delouvrier
Nicolas Fossiez
abionyx@newcap.eu
+33 (0)1 44 71 98 53

NewCap

Media relations
Arthur Rouillé
abionyx@newcap.eu
+33 (0)1 44 71 94 94